Cancer Chemother Pharmacol 2019 08 22;84(2):287-298. Epub 2019 Apr 22.
Department of Physiology and Pharmacology, Drug Research and Development Center, Faculty of Medicine, Federal University of Ceará, Rua Cel Nunes de Melo, 1127, Rodolfo Teófilo, Fortaleza, Ceará, 60430-270, Brazil.
Purpose: Anticancer-drug efficacy seems to involve the direct interaction with host immune cells. Although topoisomerase I (Top I) inhibitors have been suggested to block LPS-evoked inflammation, the interaction between these drugs and toll-like receptor 4 (TLR4) is unaddressed.
Methods: SN-38, the active metabolite of the Top I inhibitor irinotecan, and TLR4 interaction was assessed using the in vitro luciferase nuclear factor-κB reporter assay, neutrophil migration to murine air-pouch, in silico simulation, and the thermal shift assay (TSA). Read More